ACOGF ALPHA COGNITION INC NEW

Alpha Cognition Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062, an acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer's type and mild traumatic brain injury; and ALPHA-0602, a gene therapy program for the treatment of ALS. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$0.73    OTCQB
As of 01/24/2022     OTCMarkets


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Unknown
Industry:  
Index country:  Canada
Country of incorporation:  
IPO date:  12/23/2021
Outstanding shares:  60,606,931
Average volume:  10,592
Market cap:   $50,443,149
Current dividend yield:  0.00%
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   33.29
PS ratio:   0.00
Return on equity:   -1,159.16%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy